Holen Sie sich die Stockscreener-App
48.59
0.51%
-0.25
Handel nachbörslich:
49.51
0.92
+1.89%
Schlusskurs vom Vortag:
$48.84
Offen:
$48.74
24-Stunden-Volumen:
1.16M
Relative Volume:
1.00
Marktkapitalisierung:
$4.10B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.1801
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-2.08%
1M Leistung:
+0.14%
6M Leistung:
+7.64%
1J Leistung:
+55.89%
1-Tages-Spanne:
$48.20
$50.04
1-Wochen-Bereich:
$48.18
$50.57
52-Wochen-Spanne:
$29.02
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.59 | 4.10B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
10 Biotech Stocks Screaming a Buy - Insider Monkey
PTC Therapeutics (PTCT): Truist Securities Initiates Coverage with 'Buy' Rating | PTCT Stock News - GuruFocus
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - MarketScreener
Truist Financial Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Gains Buy Rating with Promising Drug Pipeline | PTCT Stock News - GuruFocus
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
When the Price of (PTCT) Talks, People Listen - news.stocktradersdaily.com
GAMMA Investing LLC Increases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Pallas Capital Advisors LLC Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Harbor Capital Advisors Inc. Sells 11,891 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market - Investing.com Nigeria
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market By Investing.com - Investing.com South Africa
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - Eastern Progress
Cantor Fitzgerald Weighs in on PTCT FY2026 Earnings - MarketBeat
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key - openPR.com
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
Encephalopathy Pipeline 2025: Comprehensive Clinical Trials - openPR.com
PTC Therapeutics at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Transcript : PTC Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - marketscreener.com
Friedreich's Ataxia Market Set to Witness Rare Disease Drug - openPR.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lessened by Public Employees Retirement System of Ohio - MarketBeat
William Blair Issues Pessimistic Estimate for PTCT Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Shareholders to Reach Out - ACCESS Newswire
William Blair Predicts Lower Earnings for PTC Therapeutics - Defense World
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - sharewise
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - MSN
Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 108,345 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - Yahoo Finance
PTC Therapeutics: Strong Buy Rating Backed by Promising Sepiapterin Launch and Robust Financial Outlook - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 26,274 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Mackenzie Financial Corp Boosts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Ameriprise Financial Inc. Has $1.94 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Price Target Raised by RBC Capital | PTCT Stock News - GuruFocus
RBC Capital raises PTC Therapeutics stock price target to $60 By Investing.com - Investing.com India
RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating - marketscreener.com
Trend Tracker for (PTCT) - news.stocktradersdaily.com
PTC Therapeutics at William Blair Conference: Strategic Growth and Innovation - Investing.com Canada
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - Yahoo Finance
PTC Therapeutics : William Blair 45th Annual Growth Stock Conference Presentation - marketscreener.com
Deepening digitalization in drug discovery at PTC therapeutics - SelectScience
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
RBC Capital maintains outperform rating for PTC Therapeutics stock By Investing.com - Investing.com Nigeria
Citi maintains neutral rating on PTC Therapeutics stock - Investing.com
PTCT Benefits from FDA's Flexible Approach to Huntington's Disea - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
May 16 '25 |
Option Exercise |
25.69 |
883 |
22,684 |
104,784 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
May 15 '25 |
Sale |
46.18 |
1,929 |
89,081 |
103,901 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
May 16 '25 |
Sale |
46.02 |
883 |
40,636 |
103,901 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):